Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia

[1] Lu R(2020)Chemotherapy-induced thrombocytopenia and platelet transfusion in patients with diffuse large B-cell lymphoma Transl Cancer Res 9 1640-1651

[2] Lin Q(2015)Managing thrombocytopenia associated with cancer chemotherapy Oncology (Williston Park) 29 282-294

[3] Chen S(2009)Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007 Clin Ther 31 2416-2432

[4] Ye X(2001)Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia J Clin Oncol 19 1137-1146

[5] Kuter DJ(2021)A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies Haematologica 106 1148-1157

[6] Wu Y(2013)The biology of thrombopoietin and thrombopoietin receptor agonists Int J Hematol 98 10-23

[7] Aravind S(2000)Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer Ann Intern Med 132 364-368

[8] Ranganathan G(2018)Transitioning patients with immune thrombocytopenia to second-line therapy: challenges and best practices Am J Hematol 93 816-823

[9] Martin A(2019)Current advance in thrombopoietin receptor agonists in the management of thrombocytopenia associated with chronic liver disease: focus on avatrombopag Clin Med Insights Blood Disord 12 1-16

[10] Nalysnyk L(2007)Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist Blood 109 4739-4741

[1] Lu R(2020)Chemotherapy-induced thrombocytopenia and platelet transfusion in patients with diffuse large B-cell lymphoma Transl Cancer Res 9 1640-1651

[2] Lin Q(2015)Managing thrombocytopenia associated with cancer chemotherapy Oncology (Williston Park) 29 282-294

[3] Chen S(2009)Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007 Clin Ther 31 2416-2432

[4] Ye X(2001)Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia J Clin Oncol 19 1137-1146

[5] Kuter DJ(2021)A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies Haematologica 106 1148-1157

[6] Wu Y(2013)The biology of thrombopoietin and thrombopoietin receptor agonists Int J Hematol 98 10-23

[7] Aravind S(2000)Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer Ann Intern Med 132 364-368

[8] Ranganathan G(2018)Transitioning patients with immune thrombocytopenia to second-line therapy: challenges and best practices Am J Hematol 93 816-823

[9] Martin A(2019)Current advance in thrombopoietin receptor agonists in the management of thrombocytopenia associated with chronic liver disease: focus on avatrombopag Clin Med Insights Blood Disord 12 1-16

[10] Nalysnyk L(2007)Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist Blood 109 4739-4741